| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Palvella Therapeutics, Inc.
13D
PVLA · 697947109
|
14.6% |
12/20/2024
Event 12/13/2024
|
||||
| Kaupinen Wes | 14.6% | |||||
| Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 | 6.9% | |||||
| Christine L. Kaupinen | 13.9% | |||||
| Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 | 6.9% | |||||
| Michael Christopher | 6.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.